Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.58 |
| ▸ | NPC1 | O15118 | 6/20 | 0.58 |
| ▸ | MITF | O75030 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | F10 | P00742 | 7/20 | 0.58 |
| ▸ | F2 | P00734 | 2/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | F9 | P00740 | 1/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.53 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.53 |
| ▸ | F7 | P08709 | 1/20 | 0.53 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | DEGS1 | O15121 | 3/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL890791 | 0.89 | F10 (0.57) | RAB9ANPC1MITFF10F2 | |
| SCHEMBL10177863 | 0.89 | F10 (0.57) | RAB9ANPC1F10F2KCNH2 | |
| SCHEMBL14366426 | 0.89 | F10 (0.58) | RAB9ANPC1F10F2KCNH2 | |
| SCHEMBL254113 | 0.89 | F10 (0.72) | F10F2KCNH2 | |
| SCHEMBL14366428 | 0.89 | F10 (0.56) | RAB9ANPC1F10F2KCNH2 | |
| Hydrochloric Acid SCHEMBL160886 | 0.89 | F10 (0.71) | F10F2KCNH2 | |
| SCHEMBL14448366 | 0.87 | F10 (0.54) | RAB9ANPC1F10F2KCNH2 | |
| SCHEMBL14404554 | 0.87 | F10 (0.54) | RAB9AF10F2KCNH2POLB | |
| SCHEMBL14366388 | 0.86 | F10 (0.71) | F10KCNH2 | |
| SCHEMBL12134213 | 0.83 | F10 (0.81) | F10F2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071519-A1 | CRYSTALLINE FORMS OF A FACTOR Xa INHIBITOR | ALEXION PHARMACEUTICALS, INC. | 2012-03-22 | — | — | US | disclosed |
| US-7727981-B2 | monoamidino-containing compounds having good bioavailability and/or solubility, used as potent and specific inhibitors of blood coagulation in mammals, and as therapeutic agents for disease states characterized by coagulation disorders | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20090131411-A1 | monoamidino-containing compounds having good bioavailability and/or solubility, used as potent and specific inhibitors of blood coagulation in mammals, and as therapeutic agents for disease states characterized by coagulation disorders | MILLENNIUM PHARMACEUTICALS, INC. | 2009-05-21 | — | — | US | disclosed |
| US-7314874-B2 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide;modified amidine elements of high potency in vitro, excellent pharmacological and pharmaceutical properties in vivo | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131411-A1 | monoamidino-containing compounds having good bioavailability and/or solubility, used as potent and specific inhibitors of blood coagulation in mammals, and as therapeutic agents for disease states characterized by coagulation disorders | F12, F2, PIGS | RAB9A 1961/4885NPC1 2404/4885MITF 1244/4885 |
| US-20120071519-A1 | CRYSTALLINE FORMS OF A FACTOR Xa INHIBITOR | F12, F9, F11 | RAB9A 2132/4885NPC1 3178/4885MITF 1949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.